Leora Horn

Leora Horn

Auto-generated profile, based on publicly available information

Leora Horn

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
Stephen LiuStephen Liu
Stephen Liu
MRMartin Reck
Martin Reck
AMAaron Mansfield
Aaron Mansfield
TMTony Mok
Tony Mok
ASArnaud Scherpereel
Arnaud Scherpereel
LHLeora Horn
Leora Horn
PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579 ), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement in overall survival (OS) and progression-free survival (PFS) versus placebo plus CP/ET. Updated OS, disease progression patterns, safety, and exploratory biomarkers (PD-L1, blood-based tumor mutational burden [bTMB]) are reported. PATIENTS AND METHODS: Patients with untreated ES-SCLC were randomly assigned 1:1 to receive four 21-day cycles of CP (area under the curve 5 mg per mL/min intravenously [IV], day 1) plus ET (100 mg/m2 IV, days 1-3) with atezolizumab (1,200 mg IV, day 1) or placebo, and then maintenance atezolizumab or placebo until unacceptable toxicity, disease progression, or loss of clinical benefit. Tumor specimens were collected; PD-L1 testing was not required for enrollment. The two primary end points, investigator-assessed PFS and OS, were statistically significant at the interim analysis. Updated OS and PFS and exploratory biomarker analyses were conducted. RESULTS: Patients received atezolizumab plus CP/ET (n = 201) or placebo plus CP/ET (n = 202). At the updated analysis, median follow-up for OS was 22.9 months; 302 deaths had occurred. Median OS was 12.3 and 10.3 months with atezolizumab plus CP/ET and placebo plus CP/ET, respectively (hazard ratio, 0.76; 95% CI, 0.60 to 0.95; descriptive P = .0154). At 18 months, 34.0% and 21.0% of patients were alive in atezolizumab plus CP/ET and placebo plus CP/ET arms, respectively. Patients derived benefit from the addition of atezolizumab, regardless of PD-L1 immunohistochemistry or bTMB status. CONCLUSION: Adding atezolizumab to CP/ET as 1L treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile at the updated analysis, confirming the regimen as a new standard of care. Exploratory analyses demonstrated treatment benefit independent of biomarker status.

4 June 2024 in Trends in Cancer
Verified
Journal Article
Open access
CAChris Abbosh
Chris Abbosh
DHDarren Hodgson
Darren Hodgson
GDGary J. Doherty
Gary J. Doherty
DGDavina Gale
Davina Gale
JBJames R.M. Black
James R.M. Black
CSCharles Swanton
Charles Swanton
Systemic treatment of resectable non-small cell lung cancer (NSCLC) is evolving with emerging neoadjuvant, perioperative, and adjuvant immunotherapy approaches. Circulating tumor DNA (ctDNA) detection at clinical diagnosis, during neoadjuvant therapy, or after resection may discern high-risk patients who might benefit from therapy escalation or switch. This Review summarizes translational implications of data supporting ctDNA-based risk determination in NSCLC and outstanding questions regarding ctDNA validity/utility as a prognostic biomarker. We discuss emerging ctDNA capabilities to refine clinical tumor-node-metastasis (TNM) staging in lung adenocarcinoma, ctDNA dynamics during neoadjuvant therapy for identifying patients deriving suboptimal benefit, and postoperative molecular residual disease (MRD) detection to escalate systemic therapy. Considering differential relapse characteristics in landmark MRD-negative/MRD-positive patients, we propose how ctDNA might integrate with pathological response data for optimal postoperative risk stratification.

9 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
MIMitchell S. von Itzstein
Mitchell S. von Itzstein
TBTimothy Burns
Timothy Burns
JDJonathan E. Dowell
Jonathan E. Dowell
LHLeora Horn
Leora Horn
DCD Ross Ross Camidge Camidge
D Ross Ross Camidge Camidge
DGDavid Gerber
David Gerber
Purpose: Patients with Kirsten rat sarcoma viral oncogene (KRAS)–mutant non–small cell lung cancer (NSCLC) have limited therapeutic options. Based on the activity of nuclear export inhibition in preclinical models, we evaluated this strategy in previously treated, advanced KRAS-mutant NSCLC. Patients and Methods: The primary outcomes of this multicenter phase I/II dose-escalation trial of selinexor plus docetaxel were safety and tolerability. Selinexor was started 1 week before docetaxel to permit monotherapy pharmacodynamic assessment. Results: Among 40 enrolled patients, the median age was 66 years, 55% were female, and 85% were White. The MTD was selinexor 60 mg orally weekly plus docetaxel 75 mg/m2 every 3 weeks. The most common adverse events were nausea (73%, 8% grade ≥3), fatigue (70%, 5% grade ≥3), neutropenia (65%, 60% grade ≥3), and diarrhea (58%, 10% grade ≥3). Of 32 efficacy-evaluable patients, 7 (22%) had partial responses and 18 (56%) had stable disease. Outcomes were not associated with KRAS mutation type but were significantly better in cases with wild-type TP53 (42%), including response and disease control rates (27% and 80% vs. 9% and 27%, respectively; P = 0.03) and progression-free survival (median 7.4 vs. 1.8 months; HR, 0.2; 95% confidence interval, 0.07–0.67; P = 0.003). After selinexor initiation and prior to docetaxel administration, serum lactate dehydrogenase levels increased an average of 51 U/L in TP53-altered cases and decreased an average of 48 U/L in TP53 wild-type cases (P = 0.06). Conclusions: Selinexor plus docetaxel was relatively well tolerated in patients with advanced KRAS-mutant NSCLC. The regimen has promising efficacy in TP53 wild-type cases, in which selinexor monotherapy may also have activity.

1 October 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SMS. Mccune
S. Mccune
TTT. Ton
T. Ton
SWS. Whipple
S. Whipple
RIR. Induru
R. Induru
LHL. Horn
L. Horn
ASA. Spira
A. Spira

17 February 2025
Verified
Other
Open access
MIMitchell S. von Itzstein
Mitchell S. von Itzstein
TBTimothy Burns
Timothy Burns
JDJonathan E. Dowell
Jonathan E. Dowell
LHLeora Horn
Leora Horn
DCD Ross Ross Camidge Camidge
D Ross Ross Camidge Camidge
DGDavid Gerber
David Gerber
Supplemental Table 2. Treatment-emergent adverse events occurring in at least 10% of the overall cohort according to dose level of selinexor.

17 February 2025
Verified
Other
Open access
MIMitchell S. von Itzstein
Mitchell S. von Itzstein
TBTimothy Burns
Timothy Burns
JDJonathan E. Dowell
Jonathan E. Dowell
LHLeora Horn
Leora Horn
DCD Ross Ross Camidge Camidge
D Ross Ross Camidge Camidge
DGDavid Gerber
David Gerber
Supplemental Table 1. Representativeness of study participants.